Targeting neutrophil serine proteases in bronchiectasis

Area of Science:

• Pulmonology
• Inflammation Research
• Drug Development

Background:

• Persistent neutrophilic inflammation is key in bronchiectasis pathogenesis and progression.
• Neutrophil serine proteases (NSPs) cause lung damage when their activity overwhelms antiproteases.
• Current treatments for neutrophilic inflammation in bronchiectasis are lacking.

Purpose of the Study:

• To review the role of NSPs in bronchiectasis.
• To discuss therapeutic strategies targeting neutrophilic inflammation.
• To evaluate the potential of cathepsin C (CatC) inhibition.

Main Methods:

• Narrative review of existing literature.
• Analysis of the role of NSPs in bronchiectasis pathology.
• Summary of clinical trial outcomes for CatC inhibitors.

Main Results:

• High NSP activity contributes to lung destruction, infection susceptibility, and poor outcomes in bronchiectasis.
• Direct NE inhibition has been unsuccessful.
• CatC inhibition shows promise by reducing multiple NSPs and restoring protease-antiprotease balance.

Conclusions:

• CatC inhibition represents a promising therapeutic approach for bronchiectasis.
• Positive Phase III clinical trial results support CatC inhibitors.
• Further strategies are needed to effectively manage chronic neutrophilic inflammation in bronchiectasis.